Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.
Munkhaugen J, Kristensen AMD, Halvorsen S, Holmager T, Olsen MH, Bakken A, Sehested TSG, Ruddox V, Mæng M, Vikenes K, Jensen SE, Steigen T, Lambrechtsen J, Jortveit J, Bovin A, Schirmer H, Christiansen MK, Wiseth R, Mikkelsen D, Larsen AI, Lyngby Kjærgaard C, Andresen K, Gustafsson I, Tuseth V, Larsen ML, Deeg PS, Veien K, Bøhmer E, Bøtker HE, Brattrud AO, Brønnum-Schou J, Pettersen AR, Bang LE, Øie E, Engstrøm T, Borg EB, Kristensen K, Nymo SH, Gislason G, Vethe NT, Abdulla JAM, Dammen T, Mouridsen MR, Bendz B, Bertelsen MLN, Hove JD, Schierbeck L, Snoer M, Davidsen C, Egholm G, Thomsen KK, Jadou G, Poenaru M, Krarup NT, Böttcher M, Stæhr PB, Zwisler AD, Edvardsen T, Torp-Pedersen C, Otterstad JE, Lange T, Fagerland MW, Atar D, Prescott E; BETAMI–DANBLOCK Investigators.
Munkhaugen J, et al. Among authors: bakken a.
N Engl J Med. 2025 Nov 13;393(19):1901-1911. doi: 10.1056/NEJMoa2505985. Epub 2025 Aug 30.
N Engl J Med. 2025.
PMID: 40888716
Free article.
Clinical Trial.
The primary end point was a composite of death from any cause or major adverse cardiovascular events (new myocardial infarction, unplanned coronary revascularization, ischemic stroke, heart failure, or malignant ventricular arrhythmias). ...CONCLUSIONS: Among patients with …
The primary end point was a composite of death from any cause or major adverse cardiovascular events (new myocardial infarction, unpl …